Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACApatch
- Development stage
- Unknown
- Lead developer
- RegenTX
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Administration
- Topical
01
Overview
ACApatch is a **dehydrated placental tissue allograft** composed of three layers: two amnion layers and one chorion layer. It is an **allogeneic matrix cellular and tissue-based skin substitute** used as a protective barrier for the management of acute and chronic wounds. The natural properties of amniotic tissue offer mechanical protection and supply growth factors that support wound healing. The membrane retains key structural components—amnion, chorion, and the spongy layer—to maximize its utility for wound coverage. ACApatch is processed to be terminally sterilized, with a shelf life of five years at ambient temperature[2][3][4].
- Brand names
- ACApatch
- Other names
- ACApatch
Beyond the preview
Go deeper on ACApatch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACApatch.